{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-25-000082","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.951659+00:00","generated_at":"2026-05-18T18:15:06.964809+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GRI Bio reports positive interim safety results from Phase 2a IPF study; IDMC recommends continuation","bullets":["IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.","GRI-0621 safe and well-tolerated; no adverse events related to hyperlipidemia (LDL, HDL, TG).","No clinically meaningful changes in HDL, LDL, or TG levels; all subjects within protocol ranges.","Interim biomarker data expected July 2025; topline results from Phase 2a study expected Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-25-000082","json":"https://secwatch.observer/filing/0001824293-25-000082.json","markdown":"https://secwatch.observer/filing/0001824293-25-000082.md","text":"https://secwatch.observer/filing/0001824293-25-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/0001824293-25-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/val-20250626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T18:15:06.964809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}